CD160 and B-cell chronic lymphocytic leukemia: CLL is a malignancy that is characterized by substantial immune system alterations, including expansion of dysfunctional CD8+ T-cells that display increased expression of various exhaustion markers, including PD-1, TIM3, LAG3, CD160, CD244 and TIGIT [38–45].